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Abstract
Oligosaccharides are currently recognised as having functions that influence the entire spectrum of cell activities. However, a
distinct disadvantage of naturally occurring oligosaccharides is their metabolic instability in biological systems. Therefore, much
effort has been spent in the past two decades on the development of feasible routes to carbohydrate mimetics which can compete
with their O-glycosidic counterparts in cell surface adhesion, inhibit carbohydrate processing enzymes, and interfere in the biosyn-
thesis of specific cell surface carbohydrates. Such oligosaccharide mimetics are potential therapeutic agents against HIV and other
infections, against cancer, diabetes and other metabolic diseases. An efficient strategy to access this type of compounds is the
replacement of the glycosidic linkage by amide or pseudoamide functions such as thiourea, urea and guanidine. In this review we
summarise the advances over the last decade in the synthesis of oligosaccharide mimetics that possess amide and pseudoamide link-
ages, as well as studies focussing on their supramolecular and recognition properties.
Review
Among the major classes of biomolecules, carbohydrates are
characterized by nearly unlimited structural diversity. Monosac-
charide units can combine to produce oligosaccharides in a
number of permutations that increases rapidly with the number
of units present, more so than is the case with other
biomolecules such as polypeptides or oligonucleotides. This is
determined by the stereochemical identity of the monosac-
charide units present (e.g. glucose, galactose, mannose), their
glycosidic linkage positions (e.g. 1→4, 1→6), the nature at
anomeric centres (α or β), the presence of additional substitu-
ents such as sulfate or acyl groups and the overall degree of
branching. The molecular diversity of oligosaccharide offers a
valuable tool for drug discovery in the areas of biologically
important oligosaccharides, glycoconjugates and molecular
scaffolds by investigating their structural and functional impact.
Currently, oligosaccharides are known to have functions in a
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Figure 1: Schematic representation of sugar aminoacids (SAAs) and (pseudo)amide oligosaccharide mimetics.
broad variety of cell–cell interactions related to invading
bacteria, viruses and cancer cells [1-4] and to play central roles
in post-translational modifications of proteins [5-7], cell–cell
communication [8] and immune response to pathogens [7,9-11].
However, the application of oligosaccharides as potential thera-
peutic agents has its main drawback in the low instability of
natural carbohydrates in biological systems. In addition, solid
phase synthesis of oligosaccharides is not yet efficient enough
for generating oligosaccharide-based libraries that may be
useful in the future for the discovery of new therapeutic drugs.
Taking into account the increasing importance of glycobiology
and the difficulties associated to the synthesis of carbohydrate-
based libraries, several approaches based on the assembly of
sugar building blocks through amide and pseudoamide linkages
have been developed by different research groups over the last
few years. Sugar aminoacids (SAAs, Figure 1) have extensive-
ly been used in the development of a large variety of molecules.
In the past 10 years, some reviews on SAAs have summarised
the different synthetic methods used to obtain such molecules
[12-14] as well as their applications to access to a diversity of
linear, branched and cyclic pseudooligosaccharides and glyco-
mimetics often referred to as carbopeptoids [13-17]. In addition,
SAAs have been widely used in the field of material sciences as
carbohydrate-derived monomers for the design of novel chiral
polyamides [18]. Nevertheless, these review articles mainly
focus on amide-linked sugars and do not pay too much atten-
tion to other types of pseudosugars. A notable exception is the
contribution by Wessel and Dias Lucas, who recently published
an interesting review where oligosaccharide mimetics which
deviate from the natural linking pattern were discussed [19].
This review also included pseudoamide-linked sugars
(Figure 1).
In this current review we have tried to highlight the recent
advances in the synthesis of oligosaccharide mimetics. We have
focussed on amide and pseudoamide-linked oligosaccharides,
and their molecular recognition properties. We intend this
survey to be wide-ranging and cover the most recent trends in
the field.
Amide-linked sugars: carbopeptoids
The replacement of the glycosidic oxygen atom by an amide
group leads to amide-linked sugars (Figure 1), which are syn-
thesised by the sequential coupling of SAAs to form a class of
compounds commonly referred to as carbopeptoids. The use of
the amide functional group to connect sugar building blocks is
inspired by the structure of peptides and the potential of carbo-
hydrates to reproduce the structural features and biological
properties of these polymers [12,13,17]. Poor bioavailability
and metabolic stability of peptides have resulted in significant
limitations as drug candidates. Another general problem is the
loss of the original conformation in the isolated peptide frag-
ments present in natural proteins, where the rest of molecule
fixes a specific spatial disposition. Furthermore, short linear
peptides cannot be restricted to adopt a particular conformation
that enables effective interaction with a receptor [20]. As a
consequence, a wide variety of methods to restrict the confor-
mational freedom has been developed. One approach to get
round this problem is the isosteric replacement of the amide
bond in the peptide with a suitable mimetic to induce a specific
secondary structure. Recent investigations have demonstrated
that incorporation of SAAs in peptide structures can circum-
vent the adverse properties of bioactive natural systems. Thus,
SAAs containing amino and carboxylic functional groups, and a
rigid ring system (pyran, furan, oxetane) have emerged as
versatile and conformationally constrained building blocks for
the formation of peptide and oligosaccharide mimetics using
standard peptide coupling techniques in solution or in the solid
phase. Exploitation of the rigidity and diversity of the sugar
backbone should permit subtle modifications and the rational
design of oligomeric derivatives with tendency to adopt specific
compact conformations (foldamers).
Linear naturally-occurring SAA homo-
oligomers
SAAs occur extensively in nature as subunits of oligosacchar-
ides in cell walls such as N-acetylneuraminic 1 and muramic
acids 2 ,  as well  as in some nucleoside antibiotics
(e.g.,  gougerotin 3  and aspiculamycin 4) (Figure 2).
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Figure 2: Natural SAAs structures and natural nucleosidic antibiotics.
Scheme 1: Synthetic route to the target amide-linked sialooligomers. (a) Fmoc-Cl, NaHCO3, H2O, dioxane, 0 °C. (b) Ac2O, Pyridine, 0 °C. (c) BOP,
DIPEA. (d) NH2NH2·H2O, MeOH.
N-Acetylneuraminic acid is a readily available naturally occur-
ring δ amino acid. By applying solid phase peptide methods on
Rink resin with Fmoc protecting group chemistry [21,22],
Gervay and co-workers have reported a series of (1→5) amide-
linked sialooligomers ranging from dimeric to octameric
species (Scheme 1) [23,24]. All of these were soluble in water,
DMSO and methanol, which allowed NH/ND exchange NMR
experiments and circular dichroism (CD) studies to be carried
out. Combined structural studies showed that a tetramer is
required for an ordered secondary structure [23,25].
Linear non-naturally-occurring SAA homo-
oligomers
The first examples of amide-linked SAA-pyranose oligomers
were reported as long ago as 1975 by Fuchs and Lehman
[26,27]. In 2002, Ichikawa and co-workers developed a
synthetic methodology to access oligomers of glycoamino
acids, a family of non-natural SAAs with a carboxyl group at
C-1 position and an amino group replacing one of the hydroxyl
groups at either the C-2, 3, 4 or 6 positions (Figure 3).
Glucose-type building blocks were prepared and used to
construct β(1→2), β(1→3), β(1→4) and β(1→6)-linked homo-
oligomers [28-30] that were found to form rigid secondary
structures predetermined by the linkage position as evidenced
from CD and NMR measurements. Moreover, conformational
analysis by molecular modelling calculation on the β(1→2)-
linked decamer 9 supported a helical arrangement, stabilised by
a intramolecular hydrogen bonding in the form of a
16-membered ring, characteristic for β-peptides (Figure 4) [29].
Analogously, NMR and IR data of a β(1→6)-linked unsatur-
ated glycamino acid tetramer showed a turn-like structure in
chloroform solution [31].
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Figure 3: The general structure of glycoamino acids and their corresponding oligomers.
Figure 4: Conformational analysis of the β(1→2)-amide-linked glucooligomer 9.
Figure 5: Short oligomeric chains of C-glycosyl D-arabino THF amino acid oligomers.
Glycoamino acid-based carbopeptoids are resistant to glycosi-
dases and exhibit interesting biological activities. Thus, the
O-sulfated β(1→2) and β(1→6)-linked homo-oligomers effect-
ively inhibit L-selectin-mediated cell adhesion, HIV infection
and heparanase acitivity in a linkage-specific manner [28].
SAAs can have a wide range of structural diversity as a
consequence of differing on ring sizes, structural manipulation
(such as chain branching, deoxygenation, hydroxyl protection,
unsaturation), relative position between amine and carboxylic
function, and, perhaps most importantly, the spatial arrange-
ment of the amine and acid moieties. The limitations of stereo-
control of glycosidic linkages can be circumvented by their
replacement by an amide function. Furthermore, as a result of
the presence of amine and acid moieties, SAAs are suitable for
conventional combinatorial synthesis in both solid and solution
phase. Many of these aspects have been extensively studied by
Fleet’s group over the last 10 years. Efficient synthetic proced-
ures for protected and unprotected homo-oligomeric deriva-
tives of D-arabino- (Figure 5) [32-34] , D-talo- [35], L-allo-
[35], D-galacto- [36], D-allo- [37], D-lyxo- [38], L-xylo- [39]
and L-ribo-configured [39] tetrahydrofuran (THF) amino acids
were optimised in order to study the influence of ring configura-
tion and protecting groups on the secondary structure in these
carbopeptoids.
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Figure 6: (A) Stereoview of the minimized structure of compound 16 (produced by a 500 ps simulation) that most satisfies the 27 NOE derived dis-
tance constraints. (B) View looking from C to N terminus. Hydrogen bonds are indicated by dotted lines.
Short oligomeric chains of C-glycosyl β-D-arabino THF amino
acids 14 and 15 (where the C-2 and C-5 substituents of the THF
ring are cis to each other) exhibit a well defined repeating turn
secondary structure stabilised by inter-residual hydrogen bonds,
whereas the epimeric α-D-arabinofuranose oligomer 12 (with
the C-2 and C-5 substituents in trans relative disposition) do not
show any secondary structure in solution [34]. NMR and IR
studies on D-galacto- [36] and D-allo-configured [37] oligo-
meric carbopeptoids demonstrated that the inversion of a single
stereocentre on the THF ring can have more pronounced effects
for solution conformations than the presence or absence of
different protecting groups. Thus, 2,4-cis-THF-L-ribonate
oligomers adopt hydrogen bond stabilised conformations
whereas 2,4-trans-THF-L-xylonate oligomers do not. Addition-
ally, a number of structurally related THF aminoacid oligomers
were examined by chiroptical spectroscopy to aid interpretation
of their conformational preferences. The use of CD, in addition
to NMR and solution IR, enabled the classification of the
conformations adopted by carbopeptoids as hydrogen bonded
regular, non-hydrogen bonded regular and non-hydrogen
bonded irregular [40]. “Regular” is used to define a conform-
ation that is either hydrogen bonded or non-hydrogen bonded
and not in equilibrium with other multiple conformations. If
conformational exchange operates, the term “irregular” is used.
For example, these studies demonstrated that an octameric
chain of C-glycosyl α-D-lyxo furanose amino acids 16 adopts a
regular hydrogen bonded conformation similar to an π-helix
(Figure 6) [38], whereas α-D-lyxo [38], D-talo and L-lyxo tetra-
mers have regular non-hydrogen bonded conformations [40].
Also, based on these techniques, Andreini et al. [41] have
recently demonstrated that homo-oligomers of β-SAA (β-N-
mannofuranosyl-3-ulosonic acid) adopt eight-membered ring
hydrogen bonded double-turn regular conformations in solution.
Chakraborty’s group has also prepared protected and unpro-
tected homo-oligomeric derivatives of D-manno- [42] and
D-gluco-configured [43] tetrahydrofuran (THF) amino acids
and studied their conformational properties by chiroptical and
NMR techniques. Although both hydroxyl-protected linear
oligomers displayed well-defined turn structures, their unpro-
tected counterparts resulted in a less robust and regular con-
formation. However, in some cases the studies of the conforma-
tional preference in carbopeptoids is quite challenging and must
be argued by computational methods [38,44] and infrared ion-
dip spectroscopy [45] in order to interpret the data from CD, IR
and NMR experiments reliably.
To complement its research programme on foldamer design and
because of the absence of structural investigations on linear
homo-oligomers constrained by 4-membered rings, Fleet and
co-workers undertook the synthesis of carbopeptoids based on
the oxetane template (Figure 7) [46-48]. Conformational
analysis was carried out for two oxetane β-SAA hexamers with
the 6-deoxy-L-altro and D-arabino configurations by means of
detailed NMR and IR studies in combination with molecular
mechanics [49]. These studies identified a left-handed helical
secondary structure for the 6-deoxy-L-altro-oxetane hexamer
and a right-handed helical structure for the D-arabino-
configured oxetane hexamer 21 (having the opposite absolute
configuration at C-2 and C-3) stabilised in both instances by
10-membered ring hydrogen bond arrangement (Figure 8).
Similar conformational studies combined with CD spectro-
scopy have been carried out for homo-oligomers of silyl-
protected δ-2,4-trans-oxetane-SAAs with different configura-
tions. The results showed that 6-deoxy-L-altronate, D-fuconate
and 6-deoxy-D-gulonate oligomers are characterised by irreg-
ular non-hydrogen bonded conformations whereas L-rham-
noate and D-lyxonate oligomers have regular conformations
governed by sterical interactions [50]. In contrast to the δ-2,4-
trans-oxetane-SAA oligomers, the δ-2,4-cis-oxetane-L-ribonate
tetramer and hexamer adopted a repeating β-turn structure [51]
Beilstein Journal of Organic Chemistry 2010, 6, No. 20.
Page 6 of
(page number not for citation purposes)
18
Figure 7: Structures of linear oxetane-β- and δ-SAA homo-oligomers 19–20.
Figure 8: 10-Membered ring H-bonds in compound 21 consistent with NMR and modelling investigations.
Figure 9: General structure of carbopeptoid-oligonucleotide conjugates.
dictated by internal 10-membered hydrogen bonded rings. Such
conformations are similar to those reported for the δ-2,5-cis-
oxetane-THF oligomers [37].
D’Onofrio et al. [52] have carried out solid phase synthesis of
oligonucleotides conjugated at the 3′ terminus with (1→6)-
amide-linked oligosaccharide mimics (Figure 9). The presence
of the saccharide unit at the 3′-end of 18-mers significantly
enhanced the stability of the oligonucleotides in bovine fetal
serum, non-negatively interfering with their ability to form
stable duplexes with complementary DNA strands, as evalu-
ated by UV thermal denaturation studies.
Orthogonally protected sugar diamino acids (SDA) were first
synthesised by Sicherl and Wittmann [53] and used to form
linear and branched amide-linked mimetics (Figure 10).
Due to the various possibilities with which SDAs can be
connected to each other, a high degree of diversity can be
Figure 10: Protected derivatives of 2,6-diamino-2,6-dideoxy-β-D-gluc-
opyranosyl carboxylic acid 22 and 23.
achieved by employing only a small set of different SDAs.
Moreover, oligomeric SDAs with unprotected groups represent
a novel type of aminoglycoside mimetics with potential recog-
nition properties towards new RNA targets emerging in the
post-genome era.
Cyclic SAA homo-oligomers
A cyclic array of desired ring size and defined secondary struc-
ture of alternating carbohydrate moieties and amide groups
might conceivably lead to exquisite specificity of recognition
and catalysis. One application of this concept is the mimicry of
Beilstein Journal of Organic Chemistry 2010, 6, No. 20.
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Scheme 2: Strategy for solid-phase synthesis of cyclic trimers and tetramers containing pyranoid δ-SAAs.
cyclodextrin inclusion complexes. Thus, Kessler and
co-workers have reported the synthesis of cyclic oligomers
containing glucopyranosyluronic acid by exploiting standard
solid and solution phase coupling procedures [54]. These cyclic
homo-oligomers of SAAs behave as host molecules that form
inclusion complexes with p-nitrophenol and benzoic acid.
Following the same objective, Xie’s group prepared orthogon-
ally protected cyclic homo-oligomers with two to four SAA
units that can be selectively or fully deprotected to afford
macrocycles that can undergo further functionalisation
(Figure 11) [55].
Figure 11: Cyclic homo-oligomers containing glucopyranoid-SAAs.
Conformational analysis by molecular modelling showed that
the unprotected cyclic trimers and tetramers preferred a 4C1
chair conformation with the oxygen atoms of the sugar ring
located in the interior of the cavity and the secondary hydroxyl
groups outside. This conformation is in agreement with the
capacity of these cyclic carbopeptoids to form inclusion
complexes with aromatic guest molecules [54] and Cu(II) ion
[56]. Additionally, van Well et al. have described a cyclization/
cleavage strategy for solid phase synthesis of cyclic trimers and
tetramers containing pyranoid δ-SAAs (Scheme 2) and reported
their structural analysis from ROESY data in combination with
molecular dynamics calculations [57]. The results showed that
the furanoid and the pyranoid SAA trimers adopt well-defined
structures, although the trimer composed of pyranoid SAAs is
less flexible than its furanoid counterpart.
Chakraborty and co-workers have also synthesised cyclic
homo-oligomers of mannose- and glucose-derived furanoid
SAAs [58] in order to constrain their conformational degrees of
freedom and to induce desirable structural elements essential for
their biological activities, such as tubular structures for trans-
porting ions or molecules across membranes. Detailed ROESY,
temperature coefficient (Δδ/ΔT) measurements of amide
protons and constrained MD simulations revealed that all the
Beilstein Journal of Organic Chemistry 2010, 6, No. 20.
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Figure 13: Aminoglycosidic antibiotics of the glycocinnamoylspermidine family.
cyclic oligomers had symmetrical structures, although none of
the unprotected cyclic oligomers displayed any ability to trans-
port ions across model membranes according to ion flux studies.
Cyclic tetramers of L-rhamno- and D-gulo-configured oxetane-
SAAs 24 and 25 (Figure 12) have been synthesised by Fleet et
al. [59] as mimics of naturally occurring cyclic peptides and
cyclodextrins, although no further conformational and recogni-
tion studies on these compounds have currently been published.
Figure 12: Cyclic tetramers of L-rhamno- and D-gulo-configured
oxetane-SAAs.
Urea, carbamate and thiourea-linked sugars
The replacement of amide groups by pseudoamide (NH–C =
X)–Y; X, Y = O, N, S) has been widely used in peptide chem-
istry to induce well-defined secondary structures. In carbo-
hydrate chemistry, the incorporation of pseudoamide-type inter-
saccharide linkages has an additional interest because these
functional groups are isosteric with phosphodiesther groups
occurring in oligoglycosylphosphates and nucleotides.
Some examples of natural compounds having saccharide units
connected by pseudoamide linkage are known. For example, the
family of glycocinnamoylspermidine antibiotics 26–28, whose
structures were determined by Ellestad and co-workers [60] by
NMR spectroscopy and X-ray diffraction, are characterised by
the presence of a glycosylurea linkage (Figure 13). In 2005,
Ichikawa and co-workers described the total synthesis of the
glycocinnasperemicin D 29, a broad-spectrum antibiotic against
Gram-negative organisms, which contains two highly function-
alised aminosugars connected by an urea linkage [61]. While
exploring the synthesis of this target molecule, this group estab-
lished a new method for the stereoselective synthesis of novel
β-urea-linked pseudooligosaccharides, which involves the reac-
tion of amine-glycosides with Steyemark-type gluco- and
galactopyranosyl oxazolidinones [62,63].
Another example of natural disaccharide analogue containing a
pseudoamide linkage is trehazolin 33 [64], which possesses a
cyclic isourea functionality between the α-D-glucose and
aminocyclopentitol rings. Trehazolin is a potent trehalase inhib-
itor in which an aminocyclopentitol ring replaces the gluc-
opyranosyl cation postulated as an intermediate in the
enzymatic hydrolysis of α,α-trehalose. Although several
synthetic methodologies had successfully been applied to
prepare this inhibitor, Chiara and co-workers have described a
novel complementary approach in which the oxazoline ring is
generated by SN2 nucleophilic displacement reaction from the
β-hydroxyurea 30 via the triflate intermediate 31 (Scheme 3)
[65].
A similar methodology was used by the same authors to prepare
the trehazolin analogue 37 with an isothiourea group instead of
an isourea group, which is also a potent trehalase inhibitor
[66,67]. D-Gluco trehazolin analogues have also been synthe-
sised by means of novel methodology based on the coupling of
O-unprotected β-D-glucopyranosyl isothiocyanate with
different aminosugars followed by treatment with yellow
mercury (II) oxide [68].
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Scheme 3: Synthesis of (thio)trehazoline, via triflate, from β-hydroxy(thio)urea.
Figure 14: Approaches to access pseudoamide-type oligosaccharide mimics.
Figure 15: Calystegine B2 analogues 38 and 39 with urea-linked disaccharide structure.
There are two general strategies to access pseudoamide-type
oligosaccharide mimics: i) nucleophilic addition of sugar de-
rivatives to carbohydrate isocyanates, isothiocyanates or isocy-
anides; and ii) conversion of sugar azides into glycosyl carbod-
iimides via a tandem Staudinger-aza-Wittig type reaction with
triphenylphosphine and an isothiocyanate, followed by the add-
ition of a nucleophile (H2O, H2S, NH3, amines) (Figure 14).
Although this second methodology is more straightforward and
versatile than the first, only a few examples of pseudooligosac-
charides having cyanamide, urea and thiourea-linkages via the
Staudinger reaction have been reported [69,70].
In our group, the carbodiimide approach was used to prepare
calystegine B2 analogues with the urea-linked disaccharide
structure (Figure 15). These compounds, however, did not show
inhibitory activities, probably due to the presence of a hydro-
philic sugar substituent at the nitrogen atom of the nor-tropane
ring [71,72].
Several groups have shown that disaccharide ureas and
carbamates with different bridging positions as α/β-anomers are
readily accessible by the coupling reaction of aminosugars or
sugars, respectively, and glycosyl-isocyanates [73,74] or isocy-
anides [75]. However, the experimental difficulties in handling
isocyanates has led to the preferential use of sugar carbodiim-
ides as key intermediates for the preparation of glycosylureido
sugars [76-79].
From the large number of functional groups that can be
employed as surrogates for the natural amide and phosphodi-
Beilstein Journal of Organic Chemistry 2010, 6, No. 20.
Page 10 of
(page number not for citation purposes)
18
Figure 16: Rotameric equilibrium shift of 40 by formation of a bidentate hydrogen bond.
ester linkages, the thiourea functionality ranks among the most
popular. Firstly, it can generally be generated in high yield and
are ideally suited for solid phase and combinatorial approaches.
Secondly, thioureas can be easily transformed into carbodiim-
ides and thus serve as key intermediate in the synthesis of other
pseudoamide functionalities (urea, guanidine, etc.) [70-72,76-
79]. Thirdly, thiourea bridges provide efficient anchoring points
for bidentate hydrogen-bonding recognition, which can give rise
to defined secondary structures or be exploited in molecular
recognition. Conformational studies by temperature coefficient
measurements and ROESY experiments showed that thiour-
eidodisaccharides adopt the Z,E conformation at N–(C=S)
bonds, which is stabilised by intramolecular hydrogen bonding
with the formation of a 7-membered ring (e.g. 40) [80]. This
conformation changes to the Z,Z-conformation in aqueous solu-
tion [70] or in the presence of carboxylate ligands due to the
formation of a bidentate hydrogen bond (Figure 16) [80].
Examples of thiourea-connected saccharides have been typic-
ally limited to compounds where the tethering reaction involves
only two moieties, with no possibility of chain elongation
[68,70-72,81], except in cases where there are spacer substitu-
ents [82]. Interestingly, a thiourea-linked dinucleotide was
elongated by solid-phase synthesis to incorporate positively
charged isothiouronium inter-nucleoside linkages into other-
wise negatively charged DNA (Figure 17) [83,84]. The binding
of these artificial DNAs (DNmt or DNT) to its complementary
DNA strand occurs as with the unmodified DNA·DNA duplex
but with enhanced nuclease resistance.
In order to design longer thiourea-linked glycooligomers with
linear dendritic and branched architectures, our group has
recently reported an efficient synthetic strategy based on the use
of AB, AB2 and ABC-type monosaccharide building blocks
containing isothiocyanate (A), azido (B) or carbamate groups
(C) (Scheme 4) [85,87]. An iterative and efficient three-step
reaction sequence was described for the assembly of monosac-
charide units that involves: (i) a thiourea-forming reaction; (ii)
deprotection of the hydroxy groups in the adducts and (iii) the
generation of a new amino group in the growing chain.
Branching points are incorporated by inserting building blocks
Figure 17: Nucleotide analogues with thiourea and S-methylisothiour-
onium linkers.
bearing orthogonal amine functionalities at specific locations in
the chain [86]. Conformational studies by dynamic NMR spec-
troscopy of β-(1→3)- and β-(1→6)-linked diglucosylthioureas
(e.g. 41) detected the presence of Z,Z and Z,E conformers at the
N–(C=S) bond (Figure 18).
β-(1→6)-Linked thioureido-di- and trisaccharides were used to
obtain the corresponding ureido- and guanidine-linked
oligomers. These compounds were evaluated as phosphate
binders in water [76]. Association constants (Kas) for the
binding of dimethyl and, especially, phenyl phosphate were
obtained from NMR titration experiments for both series of
glucooligomers. The binding affinity of the thiourea and guan-
idine oligomers was stronger than in the case of the urea
analogues.
Stimulated by the interesting supramolecular properties and
applications of cyclodextrins (CDs), a range of novel host
molecules with differently shaped internal cavities has been
obtained by replacement of the natural glycosidic bonds by urea
and thiourea linkages. Thus, our group developed an efficient
and modular strategy for the synthesis of cyclopseudooligosac-
charide receptors relying on alternating α,α-trehalose motifs and
semi-rigid thiourea segments (cyclotrehalans, CTs) [77-
79,88,89]. Molecular diversity was introduced at the inter-
saccharide connectors by exploiting the chemistry of macro-
cyclic carbodiimides [77-79,88,89] as well as by varying the
size of the macrocycle (Figure 19).
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Scheme 4: Retrosynthetic approach to synthesize thiourea-linked glycooligomers.
Figure 18: Rotameric equilibria for β-(1→6)-thiourea-linked glucodimer 41.
Figure 19: Schematic representation of (a) cyclodextrin (CDs) and (b) cyclotrehalan (CTs) family members.
Molecular modelling predicts the existence of a flexible, relat-
ively hydrophobic cavity suited for molecular inclusion of non-
polar guests [79,88]. NMR supports this fact and confirms the
high symmetry of these hosts, where all glucopyranosyl units
are magnetically equivalent as in the case of cyclodextrins. De-
termination of the inclusion capabilities towards a series of
structurally diverse guests demonstrated that large-ring CTs are
well suited for forming supramolecular complexes in water
[77,79,88].
Guanidine-linked sugars
The use of the guanidine functional group to connect monosac-
charide units in glycooligomers is particularly attractive with
regard to molecular recognition processes. Like thioureas and
ureas, guanidines can also form bidentate hydrogen bonds. In
addition, because of their positively charged character, guan-
idines can exert strong electrostatic interactions with negatively
charged functional groups such as phosphate or carboxylate
groups in DNA, RNA and proteins.
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Scheme 5: Synthesis of guanidine-linked pseudodisaccharides via carbodiimide.
Figure 20: β(1→6)-Guanidine-linked pseudodi- and pseudotrisaccharides 47 and 48.
Tóth and co-workers [90] synthesised a series of guanidine-
linked sugars as a new class of oligosaccharide mimics to study
their interactions with proteins. Thus, reaction of the carbod-
iimide-linked pseudooligosaccharide 42 with different
secondary amines gave the corresponding guanidines 43–46
(Scheme 5) and their conformational behaviour and tauto-
merism was studied by NMR spectroscopy.
β(1→6)-Linked pseudodi- (47) and pseudotrisaccharides (48)
incorporating guanidine intersaccharide bridges have been
prepared and evaluated as phosphate binders in water
(Figure 20) [76]. Association constants (Kas) for binding with
dimethyl and phenyl phosphate were obtained from NMR titra-
tion experiments for both compounds. The results indicated that
the binding strength depends strongly on the acidity of the NH
protons and on solvating properties. The guanidine derivatives
showed higher Kas values than the isosteric thiourea and urea
analogues.
Ortiz Mellet’s group has reported the synthesis of N-benzyl-
guanidine-linked dimeric cyclotrehalans (CT2s, 50) [78] via
carbodiimide 49 by reaction with benzylamine hydrochloride
and subsequent deacetylation (Scheme 6). Structural and con-
formational studies on 50 were carried out by NMR, which
showed that the structure was stabilised by two anti-parallel
seven-membered ring intramolecular hydrogen bonds, resulting
in relatively high rotational barriers for the Z,E:E,Z/E,Z:Z,E
equilibrium. The cavity collapses due to the presence of these
intramolecular hydrogen bonds thus preventing the formation of
inclusion complexes.
Most examples of linear pseudoamide-linked glycooligomers
correspond to oligonucleotide analogues. The “antisense”
strategy to regulate gene expression in living cells has required
the development of modified oligonucleotides as potential
therapeutic agents. A key goal in the design of such agents
include increasing binding affinity while maintaining sequence
specificity, resistance to degradation by nucleases and improved
membrane permeability [83,84]. Numerous structural analogues
of DNA/RNA designed to be effective antisense/antigene
agents have been reported. An interesting approach involves
replacing the negatively charged phosphodiester linkages of
RNA/DNA by positively charged guanidinium linkages. The
guanidinium linkage is resistant to nucleases [91,92] and the
positive charge may give rise to cell membrane permeability
through electrostatic attraction with the negatively charged
groups of the proteoglycans at the cell surface. Using this
strategy, Bruice and co-workers synthesised ribonucleic guan-
idine (RNG) and deoxyribonucleic guanidine (DNG) as
analogues of RNA and DNA, respectively (Figure 21).
The methodology developed to generate internucleoside guan-
idinium linkages can be used in both solution phase and solid
phase synthesis [91-94]. It involves the abstraction of the
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Scheme 6: Synthesis of N-benzylguanidine-linked CT2 50.
Figure 21: Structure of RNG and DNG.
Figure 22: Preparation of Fmoc-guanidinium derivatives.
sulphur atom from a (Fmoc)-protected thiourea by Hg2+ to
provide an activated carbodiimide which can react with a free
amino group to give the protected guanidine (Figure 22).
Homo-oligomeric RNG sequences, containing trimeric and
pentameric uridyl [95] and adenyl moieties (52-55)  (Figure 23),
and a mixed-base pentamer [96] (56, 5′-AUAUA-3′), were syn-
thesised using this methodology (Figure 24).
Binding studies of uridyl ribonucleic guanidine 52 to DNA [97]
and RNA [98] showed that it binds pentameric adenyl DNA and
RNA with a 1:1 stoichiometry. The RNG 52 dimeric complex
with DNA is thermodynamically favoured in comparison to
RNA·DNA and DNA·DNA duplexes and was able to discrim-
inate between complementary and non-complementary base
pairs. These results suggest that 52 is a good candidate for an
antisense agent.
A 21 base pair RNG/DNA chimera containing both anionic
phosphodiester linkages of DNA and cationic guanidine link-
ages of RNG has been synthesised [99]. Phosphoramidite 56
(Figure 24) was used as a building block to introduce guan-
idinium linkages at desired positions in the chimeric oligonuc-
leotides. The biological properties were evaluated using the
bcr-abl oncogene (the cause of chronic myeloid leukaemia) as
the target. The results showed that the binding of a 21-mer
RNG/DNA chimera containing six guanidinium linkages is
more than 104-fold stronger than the binding of its 21-mer
DNA counterpart.
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Figure 25: Structures of DNGs 57–65.
Figure 23: Structures of the homo-oligomeric RNG derivatives 51–55.
Deoxyribonucleic guanidine homo-oligomeric sequences,
consisting of trimeric and octameric thymidyl [100], octameric
cytidyl [101] and trimeric 7-deazaguanidyl moieties (57–60)
[102] and a mixed-base tetramer [103] and hexamer [104]
(61–63) were synthesised using the same strategy as noted
above for RNG synthesis (Figure 25).
Figure 24: Phosphoramidite building block 56.
Binding studies of homo-oligomers 57 and 58 to comple-
mentary DNA oligomers showed a 1:2 DNG:DNA stoi-
chiometry, similar to homo-polymeric thymidyl and adenyl
DNA strands, which can form a triple helical structure. On the
other hand, octameric cytidyl DNG 59 and mixed-based
oligomers 61–63 form 1:1 complexes with complementary
DNA oligomers. The trimeric 7-deazaguanidyl 60, in which
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guanine is replaced by 7-deazaguanine (c7G), forms a 1:1
complex with pentameric adenyl DNA. Deazaguanine nucleo-
base was chosen because of the unique glycoside bond stability
and its ability to prevent G-quartet formation.
To increase the already strong binding of DNG to DNA, DNG
was combined with a ligand capable of binding specifically to
the minor groove of the DNA. A pentameric thymidyl DNG in-
corporating bis-benzimidazole (Hoechst 33258) ligand (64) was
synthesised [105]. The stability of DNG-Hoechst conjugates 64
and 65 with a 30-mer double-strand DNA (dsDNA) and single-
strand DNA (ssDNA) were evaluated. Fluorescent emission
studies showed that hybridization of DNG-Hoechst conjugates
64 and 65 to dsDNA enhances the stability of the triple helix
through simultaneous minor groove binding by the tethered
Hoechst 33258 ligand. Furthermore, Hoechst 33258 is able to
enhance the stability of the duplex DNG·DNA with a flexible
minor groove. As in the case of RNG, a 20 base pair DNG/
DNA chimera has been synthesised [106].
Phosphoramidite 66 (Figure 26) was used as the starting mater-
ial for the introduction of guanidinium linkages at desired posi-
tions in the chimeric oligonucleotides. The biological proper-
ties were evaluated using the juvenile esterase gene as the
target. The results showed that binding of a 20-mer DNG/DNA
hexameric (ATATAT) chimera containing guanidinium link-
ages is more than 105.7 times stronger than the binding of the
corresponding 20-mer of DNA. The hexameric DNG binds to
DNA in a 1:1 ratio and is able to discriminate between comple-
mentary and non-complementary base pairs. In addition, the
DNG·DNA complex is more stable than the DNA·DNA duplex.
Figure 26: Structure of the phosphoramidite building block 66.
Cancer cell immortality is due to relatively high concentrations
of telomerase enzyme which maintains the telomer sequence
during cell division. One approach to prevent telomer replace-
ment in cancer cells is by inhibiting the telomerase enzyme by
blocking the telomeric RNA 11-base template (5′-CUAAC-
CCAAC-3′). For this purpose, Bruice and co-workers [107]
prepared complementary DNG (5′-GATTGGGATTG-3′) to
telomeric RNA complex. Binding studies demonstrated that the
DNG/telomeric RNA complex is favoured over the telomer
substrate, and could be of use as an anticancer agent.
Conclusion
Over the last 10 years considerable efforts have been expended
in the synthesis of novel linear and cyclic pseudoamide-linked
oligosaccharide mimics. In particular, important advances in
synthetic methodologies for thioureido and ureido glycooli-
gomers have made thus enabling the preparation of virtually
any oligomeric structure (linear, branched, dendritic and cyclic).
The secondary structures adopted by these pseudooligosacchar-
ides have been extensively studied by current NMR and
molecular modelling techniques. The results have shown that, in
many cases, the three-dimensional structure of naturally occur-
ring biomolecules can be mimicked by carbopeptoids and
pseudoamide-linked oligomeric surrogates. Nevertheless,
further investigations are required to clarify the structure-
activity relationships in order to design novel biologically active
analogues of potential therapeutic value.
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